|
|
|
|
|
07.08.25 - 13:21
|
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline (Business Wire)
|
|
|
Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients
First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual MeetingBOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors.
The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironm...
|
|
|
|
|
|
|
04.08.25 - 09:45
|
Regeneron Pharmaceuticals: Langfristig gut aufgestellt (Sharedeals)
|
|
|
Trotz einiger Herausforderungen zeigt Regeneron Pharmaceuticals im zweiten Quartal 2025 eine beeindruckende Entwicklung. Während der Rückgang der Eylea-Umsätze weiterhin belastet, überzeugen andere Produkte durch starkes Wachstum und vielversprechende Pipeline-Fortschritte. Starke Quartalszahlen trotz Eylea-Schwäche Regeneron konnte mit seinen Quartalszahlen sowohl beim Gewinn je Aktie als auch beim Umsatz die Erwartungen übertreffen. Auch wenn das Augenmedikament Eylea […]
The post Regeneron Pharmaceuticals: Langfristig gut aufgestellt first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
01.08.25 - 15:12
|
Trump Vows To Use "Every Tool In The Arsenal" To Force Big Pharma To Cut Drug Prices (ZeroHedge)
|
|
|
Trump Vows To Use "Every Tool In The Arsenal" To Force Big Pharma To Cut Drug Prices
President Trump's letter to eighteen of the world's largest pharmaceutical companies, including AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi, demanding drug price cuts for Americans, sent a jolt through pharma stocks in Europe.
Trump's formal letters to major big pharma, demanding immediate action to reduce U.S. drug prices to Most-Favored-Nation (MFN) levels — i.e., the lowest prices offered in any other developed nation, represent a move by his administration to stop what he calls "global freeloading" on U.S. pharma innovation, as well as for the adminstration to lower costs for all Americans - a campaign pledge he made in 2024.
Here are the key demands Trump made in the letter to drugmakers:
Provide MFN prices to all Medi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 13:33
|
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 (GlobeNewswire EN)
|
|
|
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron's PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
